

**ASX Announcement | 07 August 2019
Althea Group Holdings (ASX:AGH)**

Althea reaches 1,523 patients after record month

Investment Highlights:

- 1,523 patients have now been prescribed Althea medicinal cannabis products in Australia, with 245 Healthcare Professionals having prescribed Althea medicinal cannabis
- 334 patients were added in July, representing the largest number of new patients prescribed Althea products in a single month to date at a rate of 14.5 new patients per business day
- The Australian medicinal cannabis market increased at its highest rate in July, adding 2,206 TGA SAS Category B approvals¹
- Althea enters into agreement with Tetra Health, a patient support services provider of medicinal cannabis


07 August 2019: **Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH) ('Althea' or 'the Company')** is pleased to provide the following update regarding the uptake of its medicinal cannabis products in Australia and announce that it has entered an agreement with Tetra Health Pty Ltd ('Tetra') to support continued growth through its secondary clinic channels.

July a record-breaking month for patient uptake

Althea welcomed 334 new patients in July at a rate of 14.5 patients per business day, representing the largest number of new patients to be prescribed Althea products in a single month to date. The record-breaking uptake has continued into August with the Company now averaging more than 19 patients per business day.


In addition, there are now 245 Australian Healthcare Professionals ('HCPs') who have prescribed Althea's products.

Chart 1: Patient Growth



¹ <https://www.tga.gov.au/access-medicinal-cannabis-products-1>

Chart 2: HCP Growth




Medicinal cannabis applications on the rise

The rapid uptake of Althea’s products is being driven by the Company’s strategy comprised of: an on-the-ground Medical Science Liaison team; *Althea Concierge*, the Company’s proprietary technology platform that greatly reduces application times for HCP’s looking to prescribe medicinal cannabis; and its growing secondary channel of clinic partners in Australia.

Althea’s growth has been supported by the increase in Therapeutic Good Administration (‘TGA’) Special Access Scheme Category B (‘SAS B’) applications in Australia. The Australian medicinal cannabis market increased at its highest rate in July, adding 2,206 TGA SAS B approvals.

Chart 3: SAS B Growth



Agreement with Tetra to support continued growth

Tetra is a Sydney based medicinal-cannabis company facilitating access to medical cannabis treatments and medicines across Australia.

Under the agreement, Tetra will assist Althea as a non-exclusive education and distribution partner of Althea's medicinal cannabis products in Australia. Tetra Health has seen a high conversion rate of prescribed eligible patients, reporting recent growth increases in excess of 500% in the last month.

Tetra will utilise *Medical Education in Cannabinoids* ('**MEDIC**'), an online education portal developed through sponsorship by Althea which offers evidence-based education and resources for healthcare professionals, to continue to educate its increasing network of doctors in Australia about medicinal cannabis.

Althea Group Holdings CEO Josh Fegan said: "We are very pleased to have achieved a record-breaking month in July and entered into an agreement with Tetra Health, one of the leading medicinal cannabis-related service providers in Australia. This agreement gives us access to a wider network of HCPs as we continue on our mission of being the leading provider of high-quality medicinal cannabis products to patients in Australia."

-ENDS-

For further information, please contact:

Althea

Josh Fegan
CEO & Managing Director
M: 1300 70 20 20
E: contact@althea.life

Media Enquiries

Julia Maguire
The Capital Network
M: +61 419 815 386
E: julia@thecapitalnetwork.com.au

Australian Investors

PAC Partners Securities
M: 03 9114 7401
E: enquiries@pacpartners.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: www.althea.life